LifePoint Health (NASDAQ: LPNT) has recently received a number of price target changes and ratings updates:

  • 10/30/2017 – LifePoint Health was given a new $55.00 price target on by analysts at Robert W. Baird. They now have a “buy” rating on the stock.
  • 10/30/2017 – LifePoint Health had its “market perform” rating reaffirmed by analysts at Raymond James Financial, Inc..
  • 10/30/2017 – LifePoint Health had its price target lowered by analysts at Royal Bank Of Canada to $65.00. They now have an “outperform” rating on the stock.
  • 10/30/2017 – LifePoint Health had its price target lowered by analysts at Citigroup Inc. from $70.00 to $60.00. They now have a “buy” rating on the stock.
  • 10/30/2017 – LifePoint Health had its price target lowered by analysts at BMO Capital Markets from $59.00 to $55.00. They now have a “market perform” rating on the stock.
  • 10/29/2017 – LifePoint Health had its “hold” rating reaffirmed by analysts at KeyCorp.
  • 10/27/2017 – LifePoint Health was given a new $50.00 price target on by analysts at Mizuho. They now have a “hold” rating on the stock.
  • 10/16/2017 – LifePoint Health is now covered by analysts at BMO Capital Markets. They set a “market perform” rating and a $59.00 price target on the stock.
  • 10/12/2017 – LifePoint Health was given a new $69.00 price target on by analysts at Robert W. Baird. They now have a “buy” rating on the stock.
  • 10/12/2017 – LifePoint Health was given a new $60.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “hold” rating on the stock.
  • 10/4/2017 – LifePoint Health had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $66.00 price target on the stock.
  • 10/3/2017 – LifePoint Health was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “LifePoint Health’s stock has underperformed the industry in last three months. The company is faced with increasing expenses which has outpaced revenue growth thereby squeezing operating margins. The company is suffering from low patient admissions. High bad debt is another concern. Following second-quarter results, the company trimmed its 2017 guidance on a challenging volume environment and weak revenue growth. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 2.9% downward over the last 60 days.”
  • 9/11/2017 – LifePoint Health was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “LifePoint Health’s stock has underperformed the industry year to date. Its focus on strategic growth through acquisition and integration of well-positioned hospitals in the growing areas of the U.S. have contributed to its top line growth. The company has also been divesting non-core operations to focus on core growth areas. Its sufficient cash enables the company to make acquisitions and buyback shares. Following second-quarter results, the company trimmed its 2017 guidance on a challenging volume environment and weak revenue growth. The company is faced with increasing expenses which has outpaced revenue growth thereby squeezing operating margins. High bad debt is another concern. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 2.9% downward over the last 60 days.”
  • 9/5/2017 – LifePoint Health was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “LifePoint Health’s stock has underperformed the industry in last one year. Following second-quarter results, the company trimmed its 2017 guidance on a challenging volume environment and weak revenue growth. The company is faced with increasing expenses which has outpaced revenue growth thereby squeezing operating margins. High bad debt is another concern. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 2.9% downward over the last 30 daysThe stock has seen the Zacks Consensus Estimate for current-year earnings being revised 2.9% downward over the last 30 days.”
  • 9/1/2017 – LifePoint Health was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.

Shares of LifePoint Health, Inc. (LPNT) opened at 47.05 on Tuesday. The stock has a 50 day moving average of $56.24 and a 200-day moving average of $60.32. LifePoint Health, Inc. has a 52 week low of $46.50 and a 52 week high of $70.95. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of 10.54 and a beta of 0.84.

LifePoint Health (NASDAQ:LPNT) last posted its quarterly earnings results on Friday, October 27th. The company reported $0.80 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.95 by ($0.15). The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.60 billion. LifePoint Health had a return on equity of 7.01% and a net margin of 2.45%. The business’s revenue for the quarter was down .7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.94 earnings per share. Equities research analysts expect that LifePoint Health, Inc. will post $4.00 earnings per share for the current year.

LifePoint Health, Inc, through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers and post-acute facilities. As of December 31, 2016, the Company operated 72 hospital campuses in 22 states, having a total of 9,424 licensed beds. It offers a range of general and specialized healthcare services to patients through a network of hospitals and outpatient facilities.

Receive News & Ratings for LifePoint Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifePoint Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.